Colon Cancer

Establishing first-line therapy use challenge for U.S. colorectal cancer market

Published in Health and Medicine Week, June 20th, 2005

Developing drugs and establishing them as standardized first-line therapy in the U.S. colorectal cancer market is becoming increasingly complicated as companies struggle to identify the best combination in which they should test and market their drugs.

This is a strong challenge due to the complexity of colorectal cancer treatment that often requires the use of three drugs for first-line therapy and two drugs for second-line therapy.

New analysis from Frost & Sullivan, "Emerging Therapeutics in the U.S. Colorectal Cancer Market," reveals revenue in this market totaled $1,897 million in 2004 and projects to reach $2,110 million in 2011 but also...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2005-06-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry